수술 전 혈청 갑상선 자극 호르몬(TSH)수치와 갑상선 유두암과의 상관관계
Association between Preoperative Serum TSH Level and Papillary Thyroid Cancers
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Recent research has shown that there is a relationship between the level of preoperative serum TSH and a papillary thyroid carcinoma. Therefore, this study examined the correlation between the serum TSH and papillary thyroid carcinoma. Methods: The preoperative serum TSH level of papillary thyroid carcinoma and nodular hyperplasia of 418 patients from 2009 Jan. to 2011 Dec. was examined. The patients were divided into 3 groups, nodular hyperplasia, less than 1 cm micropapillary carcinoma and more than 1 cm papillary carcinoma, and their TSH levels were compared. Results: Nodular hyperplasia and total papillary carcinoma was found in 98 (23.0%) and 322 (77.0%) patients, respectively. After dividing the patients according to the size of the mass, there were 224 (53.6%) patients with a mass less than 1 cm in size and 98 (23.4%) patients with a mass more than 1 cm in size. The preoperative serum TSH level of the 3 groups showed a significant difference, which was 1.180±1.168 μIU/ml in the nodular hyperplasia group, 1.670±1.224 μIU/ml in the micropapillary carcinoma group and 2.279±2.837 μIU/ml in the papillary carcinoma group (P＜0.001). On the other hand, there were no significant correlations between the preoperative serum TSH level and gender, age, metastasis to lymph node, number of masses and extrathyroidal extensions. Conclusion: The larger size of the papillary thyroid carcinoma, the higher the preoperative high serum TSH level. Therefore, the stimulation of TSH can affect the progression of papillary thyroid carcinoma but more study will be needed.
Abstract
Purpose: Recent research has shown that there is a relationship between the level of preoperative serum TSH and a papillary thyroid carcinoma. Therefore, this study examined the correlation between the serum TSH and papillary thyroid carcinoma. Methods: The preoperative serum TSH level of papillary thyroid carcinoma and nodular hyperplasia of 418 patients from 2009 Jan. to 2011 Dec. was examined. The patients were divided into 3 groups, nodular hyperplasia, less than 1 cm micropapillary carcinoma and more than 1 cm papillary carcinoma, and their TSH levels were compared. Results: Nodular hyperplasia and total papillary carcinoma was found in 98 (23.0%) and 322 (77.0%) patients, respectively. After dividing the patients according to the size of the mass, there were 224 (53.6%) patients with a mass less than 1 cm in size and 98 (23.4%) patients with a mass more than 1 cm in size. The preoperative serum TSH level of the 3 groups showed a significant difference, which was 1.180±1.168 μIU/ml in the nodular hyperplasia group, 1.670±1.224 μIU/ml in the micropapillary carcinoma group and 2.279±2.837 μIU/ml in the papillary carcinoma group (P＜0.001). On the other hand, there were no significant correlations between the preoperative serum TSH level and gender, age, metastasis to lymph node, number of masses and extrathyroidal extensions. Conclusion: The larger size of the papillary thyroid carcinoma, the higher the preoperative high serum TSH level. Therefore, the stimulation of TSH can affect the progression of papillary thyroid carcinoma but more study will be needed.
참고문헌 (23)
- Sugitani I, "Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial", J Clin Endocrinol Metab, 95, pp.4576~4583 (2010)
- Kyu-Won Jung, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2009", Cancer Research and Treatment, 44(1), pp.11~24 (2012), 대한암학회
- Dunhill TP, "The surgery of the thyroid gland: the Lettsomian lectures", Trans Med Soc Lond, 60, pp.234~282 (1937)
- Zafon C, "Preoperative thyrotropin serum concentrations gradually increase from benign thyroid nodules to papillary thyroid microcarcinomas then to papillary thyroid cancers of larger size", J Thyroid Res, 2012, pp.530721~ (2012)
- Boelaert K, "Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration", J Clin Endocrinol Metab, 91, pp.4295~4301 (2006)
- Pacini F, "Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 21(5), pp.v214~v219 (2010)
- Jonklaas J, "Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer", Thyroid, 18, pp.943~952 (2008)
- Polyzos SA, "Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules", J Cancer Res Clin Oncol, 134, pp.953~960 (2008)
- Boelaert K, "The association between serum TSH concentration and thyroid cancer", Endocr Relat Cancer, 16, pp.1065~1072 (2009)
- Haymart MR, "Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage", J Clin Endocrinol Metab, 93, pp.809~814 (2008)
- Gerschpacher M, "Thyrotropin serum concentrations in patients with papillary thyroid microcancers", Thyroid, 20, pp.389~392 (2010)
- Chen AY, "Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005", Cancer, 115, pp.3801~3807 (2009)
- Mazzaferri EL, "Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer", Am J Med, 97, pp.418~428 (1994)
- Howell GM, "Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer", Ann Surg Oncol, 18, pp.3566~3571 (2011)
- Derwahl M, "Clinical review 101: Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors", J Clin Endocrinol Metab, 84, pp.829~834 (1999)
- Farid NR, "Molecular basis of thyroid cancer", Endocr Rev, 15, pp.202~232 (1994)
- Kanamori A, "Epidermal growth factor receptors in plasma membranes of normal and diseased human thyroid glands", J Clin Endocrinol Metab, 68, pp.899~903 (1989)
- Pujol P, "Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer", J Clin Endocrinol Metab, 81, pp.4318~4323 (1996)
- Cooper DS, "Thyrotropin suppression and disease progression in patients withdifferentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry", Thyroid, 8, pp.737~744 (1998)
- Cooper DS, "American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19, pp.1167~1214 (2009)
- Kim SS, "Preoperative serum thyroid stimulating hormone levels in well-differentiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis as well as extrathyroidal extension in Korean patients: a single-center experience", Endocrine, 39, pp.259~265 (2011)
- Lim DJ, "Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma", Thyroid, 17, pp.883~888 (2007)
- Haymart MR, "Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension", Clin Endocrinol (Oxf), 71, pp.434~439 (2009)